|
|
||||||||
Departments of 1 Nutrition and 2 Biochemistry, University of Montreal, Montreal, Quebec H3C 3J7, Canada
| |
ABSTRACT |
|---|
|
|
|---|
Little is known about the role of mitochondrial NADP+-isocitrate dehydrogenase (NADP+-ICDH) in the heart, where this enzyme shows its highest expression and activity. We tested the hypothesis that in the heart, NADP+-ICDH operates in the reverse direction of the citric acid cycle (CAC) and thereby may contribute to the fine regulation of CAC activity (Sazanov and Jackson, FEBS Lett 344: 109-116, 1994). We documented a reverse flux through this enzyme in rat hearts perfused with the medium-chain fatty acid octanoate using [U-13C5]glutamate and mass isotopomer analysis of tissue citrate (Comte et al., J Biol Chem 272: 26117-26124, 1997). In this study, we assessed the significance of our previous finding by perfusing hearts with long-chain fatty acids and tested the effects of changes in O2 supply. We showed that under all of these conditions citrate was enriched in an isotopomer containing five 13C atoms. This isotopomer can only be explained by substrate flux through reversal of the NADP+-ICDH reaction, which is evaluated at 3-7% of flux through citrate synthase. Small variations in reversal fluxes induced by low-flow ischemia that mimicked hibernation occurred despite major changes in contractile function and O2 consumption of the heart as well as citrate and succinate release rates and tissue levels. Our data show a reverse flux through NADP+-ICDH and support its hypothesized role in the fine regulation of CAC activity in the normoxic and O2-deprived heart.
citric acid cycle; citrate release; isotopomer analysis; 13C substrate; anaplerosis
| |
INTRODUCTION |
|---|
|
|
|---|
CARDIAC
ISCHEMIC DISEASES have been associated with chronic
alterations of energy metabolism such as increased myocardial citrate
release (24, 42). The cause of this deregulated cardiac citrate metabolism is unclear. Myocardial citrate release reflects its
efflux from mitochondria (43) where it is synthesized by citrate synthase during normal operation of the citric acid cycle (CAC;
Fig. 1). Citrate release, which is
modulated by substrates and/or O2 supply (24, 28, 29,
43), represents at most 1% of CAC flux. Mitochondrial citrate
efflux appears normally to be compensated largely by flux through
anaplerotic reactions such as pyruvate carboxylation, which represents
between 2 and 8% of CAC flux (5, 28, 29).
|
Citrate synthesis could also occur through a reductive process, which
involves the participation of the CAC enzymes aconitase and
NADP+-linked isocitrate dehydrogenase
(NADP+-ICDH). Aconitase catalyzes the reversible
interconversion between citrate and isocitrate. Its activity is
modulated by oxidative stress (3, 25).
NADP+-ICDH catalyzes the reversible interconversion between
isocitrate and
-ketoglutarate (
-KG). It has no known allosteric
effector. This is in contrast with NAD+-ICDH, which has
kinetic properties that are consistent with its unidirectional
operation in vivo toward
-KG formation. The latter enzyme is highly
regulated by a variety of positive (Ca2+, ADP, and citrate)
and negative (ATP, NADH, and NADPH) effectors (10).
Little is known about mitochondrial NADP+-ICDH in the
heart. It is unclear whether this enzyme operates in the forward
direction of the CAC cycle, generating
-KG and NADPH, or in the
reverse direction, generating isocitrate and NADP+. For
livers perfused under normoxia, we estimated (7) that 45%
of total citrate formation occurs through the reversal of NADP+-ICDH and aconitase reactions. Investigating the
reverse flux of NADP+-ICDH in the heart appears to be even
more relevant than in the liver for many reasons. First,
NADP+-ICDH shows its highest activity and mRNA expression
in the heart (19, 20). Second, according to Thomassen et
al. (42), reverse flux through NADP+-ICDH may
participate in the formation of citrate from glutamate and hence
possibly explains the higher myocardial citrate release in cardiac
patients. Third, according to Sazanov and Jackson (35), reverse flux through mitochondrial NADP+-ICDH could be part
of a substrate cycle that contributes to fine regulation of CAC
activity, thereby providing enhanced sensitivity to changes in energy
demand. This cycle also includes the participation of
NAD+-ICDH and H+ transhydrogenases to
regenerate
-KG and NADPH, respectively (Fig. 1). That
NADP+-ICDH could operate in vivo in the reverse direction
is supported by its kinetic properties in terms of the Michaelis-Menten
constant (Km) and available information on its
substrate concentrations in the matrix of isolated mitochondria as well
as its thermodynamic parameters (33, 35, 44). Finally, Jo
et al. (14) recently presented evidence from a NIH3T3 cell
line that NADP+-ICDH could function as an antioxidant
defense enzyme. This role requires, however, that
NADP+-ICDH operates in the forward direction of the CAC to
form NADPH for regenerating reduced glutathione by glutathione reductase.
The objective of this study was to investigate substrate flux through
the reversal of NADP+-ICDH in the intact heart. We expanded
on a previous study (4) where we documented this reverse
flux in rat hearts perfused under normoxia with the medium-chain fatty
acid (MCFA) octanoate and physiological concentrations of glucose,
lactate, pyruvate, and glutamate. This was achieved using the
13C protocol developed for perfused rat livers
(7). In the current study, we assessed the physiological
significance of our previous finding by perfusing hearts in the
presence of the physiological long-chain fatty acid (LCFA) oleate. In
addition, we tested the effects of O2 deprivation, a
condition for which Sazanov and Jackson's hypothesis (35)
predicts increased reverse flux through NADP+-IDCH. Flux
values were extrapolated from the 13C mass isotopomer
distribution (MID) of tissue citrate and
-KG levels, which were
assessed by gas chromatography-mass spectrometry (GC-MS). The
mechanical and metabolic responses of the heart were documented under
all conditions through various measurements: 1) indices of
the heart's contractile activity, 2) release rates and
tissue concentrations of CAC intermediates, and 3) activity of the tissue CAC enzymes citrate synthase, aconitase,
NAD+-ICDH, and NADP+-ICDH.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Chemicals
The sources of chemicals, biological products, and 13C substrates have been identified previously (5, 43). The dialyzed 13.4% albumin solution (BSA fraction V, fatty acid poor; Bayer) and the stock solution of 20 mM sodium oleate complexed to albumin were prepared and stored as described previously (43).Heart Perfusions
Animal experiments were approved by the local animal ethics committee in compliance with the guidelines of the Canadian Council on Animal Care. Procedures for the isolation and perfusion of rat hearts in the Langendorff mode have been described elsewhere (5, 16, 43). Briefly, the hearts of fed male Sprague-Dawley rats (body wt 160-200 g; Charles River Breeding Laboratories) were perfused for 15-20 min at a constant pressure of 70 mmHg with nonrecirculating modified Krebs-Henseleit buffer, pH 7.4, that contained 119 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 5.5 mM glucose, 8 nM insulin, 1 mM lactate, 0.2 mM pyruvate, 0.5 mM glutamate, and 50 µM carnitine. After this equilibration period, which allowed for balloon insertion into the left-ventricular cavity, the hearts were switched to another buffer reservoir that contained equilibration buffer supplemented with a fatty acid without or with albumin as indicated below. The setup for heart perfusions with albumin-containing buffer and for continuous monitoring of functional parameters using instruments linked to a microcomputer has been described earlier (43). Samples of effluent and influent perfusate, which were collected on ice, were processed immediately for determinations of PO2, PCO2, pH, and free Ca2+ or stored at
20°C until analysis for citrate and succinate release rates. At
the end of the experiments, the hearts were freeze-clamped and stored
in liquid nitrogen.
Perfusion Protocols
Hearts were perfused under normoxia or low-flow ischemia (LFI) with nonrecirculating equilibration buffer supplemented with a fatty acid: either 0.2 mM octanoate (a MCFA) or 0.4 mM oleate (a LCFA complexed to 4% albumin). Perfusion experiments were conducted sequentially. First, we tested our 13C protocol with a MCFA because this avoids the use of albumin. We then used a LCFA complexed to albumin to assess the physiological significance of our findings with the MCFA.After an equilibration period of 15-25 min, two groups of hearts were perfused under normoxia for 30 min before freeze-clamping. Four other groups of hearts underwent an additional 90 min of perfusion at 1 ml/min in the absence or presence of 1 µM norepinephrine (LFI/NE). The addition of NE simulates the increase of catecholamines that occur under ischemia and in cardiac patients (21, 37, 38). Unlabeled glutamate was replaced by [U-13C5,15N]glutamate (99%) for 1) the last 30 min of normoxic perfusion, and 2) 1 min after the beginning of LFI. Note that the concentrations of ionized calcium and endogenous free fatty acids for the 4% albumin-containing buffer were determined to be 1.2 and 0.3 mM, respectively. Thus total free fatty acid concentration for the LCFA group was 0.7 mM.
Analytical Procedures
GC-MS.
Citrate and succinate releases and 13C MID of tissue CAC
intermediates were determined by methods that have been described
previously (4, 5, 16, 43). All metabolites were analyzed
as tert-butyldimethylsilyl derivatives on a Hewlett-Packard
5890 series II plus GC coupled to a 5972 mass-selective detector
equipped with an HP-5 fused silica capillary column (50 m, 0.2-mm inner
diameter, 0.33-µm film thickness). Concentrations of CAC
intermediates were determined in tissue samples spiked with
[1,5-13C2]citrate,
[1,4-13C2]succinate, and
[U-13C4]fumarate. Quantification was achieved
using standard curves for isocitrate,
-KG, and malate.
Other assays.
PO2, PCO2, free
Ca2+, and pH were determined in influent and effluent
perfusates collected under normoxia (18 min) or LFI (88 min) using a
pH, blood gas, and electrolyte analyzer (ABL 70 series, Radiometer;
Copenhagen). For the determination of enzyme activities (citrate
synthase, aconitase, and NAD+- and NADP+-ICDH),
frozen powdered tissues were homogenized in solution that contained (in
mM) 180 KCl, 5 MOPS, and 2 EDTA, pH 7.4. After sequential centrifugation at 800 and 6,000 g for 10 min at 4°C, the
final supernatant was collected and stored at
80°C pending the
assays. Enzyme activities were assayed by monitoring the kinetics of
optical density of NADH or NADPH (340 nm) measured on a Hewlett-Packard 8452A spectrophotometer. Citrate synthase and NAD+-ICDH
were assayed by standard procedures (22). The procedure of
Nulton-Persson and Szweda (25) was slightly modified for aconitase. Heart tissue samples were added to the incubation mixture that contained 5 mM citrate, 0.5 mM MgCl2, 1 mM
NADP+, and 1 U/ml ICDH, pH 7.4 (2 ml total volume at
30°C). NADP+-ICDH activity was measured with a commercial
kit (Sigma Diagnostics). Protein contents were determined with a
Bio-Rad kit, and BSA served as a standard. Enzyme activities are
expressed as units per milligram of total protein, where 1 unit of
enzyme activity is defined as the amount catalyzing the conversion of 1 µmol of substrate per minute at 30°C.
Calculations
Myocardial O2 consumption (M
O2, µmol/min) was calculated
from the product of O2 concentration (mM) differences
between influent and effluent perfusates and coronary flow rates
(ml/min). A value of 1.06 mM was taken as the concentration of
dissolved O2 at 100% saturation (40).
Intracellular pH (pHi) was estimated using venous
CO2 pressure (PCO2, mmHg) as
described by Bünger et al. (2) as follows:
pHi = 7.524e(
0.0008786 × PCO2). The rate pressure
product (RPP, mmHg × beats/min) was calculated from the product
of left ventricular developed pressure (LVDP, mmHg) and heart rate (HR,
beats/min). As an estimate of cardiac efficiency, RPP was divided by
M
O2.
Areas under the GC fragmentograms were determined by computer
integration and corrected for naturally occurring heavy isotopes (8). GC-MS data are expressed as molar percent enrichment
(MPE) as defined previously (5, 16, 43). Briefly, the
absolute MPE of individual 13C-labeled mass isotopomers
(Mi) of a given metabolite was calculated as
follows
|
(1) |
Relative substrate flux through the reversal ICDH and aconitase
reactions was calculated from the MPE in M5 of citrate and
-KG as
described elsewhere (7)
|
(2) |
-KG
CIT is the fractional contribution
(FC) of
-KG to citrate via the reversal of NADP+-ICDH
and aconitase reactions, and
-KGM5 and CITM5
are the molar fractions of M5
-KG and M5 citrate, respectively. The
molar fraction is the MPE divided by 100. The term (1
FC
-KG
CIT) represents the fraction of citrate
molecules coming from the CAC through the citrate synthase reaction.
Statistical Analysis
Individual enrichments are the average of two to five GC-MS injections. Data are expressed as means ± SE of n heart perfusions. Statistical significance at P < 0.05 of differences between mean values was assessed by one-way ANOVA followed by a Bonferroni multiple-comparison posttest as indicated.| |
RESULTS |
|---|
|
|
|---|
As a whole, most parameters (functional, physiological, and metabolic) measured in hearts perfused with nonrecirculating buffer that contained 5.5 mM glucose, 8 nM insulin, 50 µM carnitine, 1 mM lactate, 0.2 mM pyruvate, 0.5 mM glutamate, and either 0.2 mM octanoate or 0.4 mM oleate were greatly affected by LFI.
Because the effects of LFI in the absence or presence of NE were similar, we present the results obtained with NE only as it has greater clinical relevance. Although a detailed comparison of the effects of MCFA vs. LCFA was beyond the scope of this paper, the data are presented together, because we observed only small differences between these two groups of heart perfusions.
Functional and Physiological Parameters
Values for the various functional and physiological parameters of hearts perfused under normoxia or LFI/NE with octanoate or oleate are shown in Figs. 2 and 3. All hearts perfused under normoxia beat spontaneously at a rate of 319 ± 6 beats/min (n = 29) during the entire protocol with a coronary flow rate of 9.4 ± 0.6 ml/min and systolic and diastolic pressures of 106 ± 1.9 and 6.4 ± 0.6 mmHg, respectively. Upon reduction of coronary flow to 1 ml/min, there was a progressive decrease in HR, LVDP, and dP/dtmax, which stabilized after 10 min (Fig. 2). M
O2 showed a concomitant decrease
(Fig. 3A), and consequently cardiac efficiency was increased
(Fig. 3B), although the difference did not reach significance for the LCFA group (P = 0.07). Finally,
pHi was lower under LFI/NE (MCFA, 7.210 ± 0.012;
LCFA, 7.289 ± 0.030) than under normoxia (MCFA, 7.293 ± 0.006; LCFA, 7.359 ± 0.008). This difference in pHi
reached significance only for the LCFA group (P < 0.05).
|
|
Release Rates and Tissue Levels of CAC Intermediates
The release rates of citrate and succinate, which are, respectively, indices of mitochondrial fuel abundance (43) and O2 deprivation (16), were differentially affected by LFI/NE (Fig. 4). A similar trend was observed for the release rates of hearts perfused with octanoate or oleate. However, as a whole, these rates were greater with octanoate than with oleate under both normoxia and LFI/NE. Citrate release rates were decreased three- to fourfold by LFI. However, when expressed relative to M
O2 (Fig.
4B), which reflects CAC activity, the rates were increased two- to threefold to reach 1-2.5% of
M
O2 values. The succinate release
rates under normoxia were three- to fivefold lower than those of
citrate. They were increased two- to fivefold by LFI/NE (Fig.
4C) and reached values similar to those observed for citrate under normoxia. This effect of LFI/NE was amplified by the expression of succinate release rates relative to
M
O2 (Fig. 4D).
|
Tissue levels of the various CAC intermediates were differentially
affected by LFI/NE (Fig. 5). Compared
with normoxia, the tissue levels of citrate were decreased (two- to
threefold), whereas those of succinate were increased (six- to
ninefold) under LFI/NE. The total pool size of CAC intermediates was
similar or greater under LFI/NE than under normoxia, which is in
agreement with the data of other researchers (28, 30).
Note that under all conditions, tissue citrate levels remained
severalfold (24-90) higher than those of isocitrate
and
-KG. A similar trend was observed for hearts perfused with
octanoate or oleate. However, under both normoxia and LFI/NE, hearts
perfused with octanoate showed higher tissue levels for some CAC
intermediates (citrate, isocitrate, succinate, and fumarate).
|
13C Enrichment and Flux Data
Table 1 presents the M4 and M5 isotopomers of citrate,
-KG, succinate, fumarate, and malate
isolated from homogenates of hearts perfused with
[U-13C5]glutamate under the different
conditions. Influent [U-13C5]glutamate was
enriched at 99% in M5 isotopomers.
[U-13C5]glutamate enters the CAC as M5
isotopomers of
-KG. M5
-KG is carboxylated to M5 citrate through
the reversal of NADP+-ICDH and aconitase reactions and
is decarboxylated to M4 succinate through normal operation of the CAC.
Under all conditions tested, tissue
-KG and citrate were enriched in
M5 isotopomers, whereas tissue succinate was enriched in M4
isotopomers. The lower MPE M4 of succinate compared with that of M5
-KG probably reflects the entry of unlabeled carbons through
anaplerosis. Such a dilution at the level of succinate is in agreement
with our previous data (5, 16). Similarly, the lower value
of MPE M4 for malate and fumarate than for succinate reflects the
entrance of unlabeled oxaloacetate coming from pyruvate carboxylation.
As a whole, LFI hearts showed higher MPE values for most CAC
intermediates. A similar trend was observed under LFI/NE for the MCFA
and LCFA groups. Note that the higher value of MPE M5 in tissue
-KG
is consistent with the reported increase in glutamate uptake by the O2-deprived heart (42) and hence probably
reflects increased anaplerosis rather than simple exchange.
|
We calculated the contribution of
-KG to citrate formation from the
ratio in M5 enrichment between tissue citrate and
-KG (Eq. 2). Under our perfusion conditions, M5 citrate can only be formed
through the reversal of NADP+-ICDH and aconitase reactions.
The formation of M5 citrate through other pathways involves the
following sequence of reactions: M4 malate
M3 pyruvate
M2
acetyl-CoA, or M4 malate
M3 pyruvate
M3 oxaloacetate
followed by recombination of M3 oxaloacetate with M2 acetyl-CoA. The
contribution of these pathways was considered negligible because of the
low values of MPE M4 for tissue malate (Table 1) and MPE M3 for tissue
pyruvate (<0.2%, data not shown).
Under normoxia, 3-7% of citrate molecules were formed through the
reversal of NADP+-ICDH (Fig.
6). The remaining (1
FC
-KG
CIT) 93-97% of citrate arose from citrate
synthase. Fatty acids differently modulated the effects of LFI on the
proportion of citrate formed through the reversal of
NADP+-ICDH: LFI increased this proportion by 40% in the
presence of MCFA, whereas it had no effect in the presence of LCFA.
|
Enzyme Activities
Figure 7 shows the activities of aconitase, NAD+-ICDH, and NADP+-ICDH expressed as a percentage of citrate synthase as measured in extracts of hearts perfused with MCFA or LCFA (2.10 ± 0.12 and 1.53 ± 0.19 U/mg protein, respectively, under all conditions; P < 0.05). Note the 100-fold difference in the y-axis scale for the three sets of graphs. Tissue aconitase activity (Fig. 7A) was >10-fold lower than that of citrate synthase and was decreased by LFI/NE. As a whole, aconitase activity was lower for the LCFA group than the MCFA group. NAD+- and NADP+-ICDH activities (Fig. 7, B and C) were not significantly modified by LFI/NE or the nature of the fatty acid. However, there was more than a 100-fold difference in activities between NAD+-ICDH and NADP+-ICDH, which represents 1.2-2% and 200-300% of citrate synthase activity, respectively.
|
| |
DISCUSSION |
|---|
|
|
|---|
This study was undertaken to shed some light on the role of
mitochondrial NADP+-ICDH in the heart. We expanded on a
previous investigation, which provided evidence for the reversal of
NADP+-ICDH in normoxic rat hearts perfused with glucose,
lactate, pyruvate, octanoate, and
[U-13C5]glutamate (4). In the
current study, we assessed the physiological significance of our
previous finding by documenting the reversal of NADP+-ICDH
in hearts perfused with the LCFA oleate. In addition, we tested in part
the hypothesis of Sazanov and Jackson (35) on the role of
NADP+-ICDH. In brief, this hypothesis proposes that in
mitochondria, a substrate cycle operates between isocitrate and
-KG
where NAD+-ICDH generates
-KG and NADP+-ICDH
generates isocitrate. The NADPH used in the reverse reaction of
NADP+-ICDH is supplied by the
H+-transhydrogenases driven by the proton electrochemical
gradient (see Fig. 1). The isocitrate
-KG cycle provides a
mechanism by which CAC activity could be tightly controlled by
modifiers of NAD+-ICDH and the energy state of the inner
mitochondrial membrane. This hypothesis was formulated on the basis of
the known properties of the isolated enzymes and the available
information on substrate concentrations in the matrix of isolated
mitochondria as well as thermodynamic parameters. One prediction of
this hypothesis is that compared with the CAC, flux through the
reversal of NADP+-ICDH should increase under conditions of
O2 deprivation.
As a model of O2 deprivation, we chose LFI that was
achieved by reduction of flow to 1 ml/min in the absence or presence of NE. As a whole, measured changes in the various indices reflecting the
functional, physiological, and metabolic status of perfused hearts
after reduction of flow were independent of NE and indicated the
heart's adaptation to this state of O2 deprivation. First, in LFI hearts, the indices of contractile function and
M
O2 were decreased, whereas cardiac
efficiency was unchanged or increased (see Figs. 2 and 3). This
probably results from a switch from fatty acid to carbohydrate
utilization (23, 27, 32). Second, LFI hearts perfused with
MCFA or LCFA maintained values similar to normoxic hearts for the total
pool size of CAC intermediates and the tissue citrate-to-isocitrate
concentration ratios (30-33 with MCFA and 70-90 with LCFA).
This indicates tight regulation of CAC enzymes under both normoxia and
LFI. The site of this regulation differed between normoxia and LFI as
indicated by substantial differences in the release and tissue levels
of citrate and succinate (see Figs. 4 and 5). Expressed relative to
M
O2, the combined release of citrate
and succinate was raised from 0.5% under normoxia to 10% under LFI
(see Fig. 4). Because CAC pool size is unchanged or increased under
LFI, CAC efflux must have been compensated by the entry of anaplerotic
carbons at the level of pyruvate (5, 28, 29, 43) and/or
-KG (42). Observed differences in tissue levels of
citrate and succinate under normoxia and LFI, which are in agreement
with other studies (28-30), are consistent with the
CAC operating in two spans: one from acetyl-CoA to
-KG, and the
other from
-KG to oxaloacetate (31).
We observed a similar trend for the effects of LFI on the release and
tissue levels of CAC intermediates for hearts perfused with octanoate
and oleate (see Figs. 4 and 5). However, the magnitude of changes
observed under both normoxia and LFI was greater for the MCFA group.
These results are consistent with the fact that in contrast to LCFA,
MCFA
-oxidation is not regulated at the level of carnitine palmitoyl
transferase 1 (39). The addition of NE under LFI only
marginally affected most contractile, physiological, and metabolic
parameters. Possibly, under this specific condition, the increase in
calcium levels resulting from NE addition is counteracted by adaptive
mechanisms such as the opening of sarcolemmal ATP-sensitive K+ channels, which decreases intracellular calcium levels
and hence downregulates contractile activity (9). Thus
based on the aforementioned results, we conclude that similar to the
pig heart perfused in vivo (28), LFI in the rat heart
perfused ex vivo mimics to some extent a state of hibernation
(34), which is independent of the nature of the fatty acid added.
The results of this study demonstrate a small flux through the reversal
of NADP+-ICDH in both normoxic and LFI rat hearts perfused
in the presence of MCFA or LCFA, representing 3-7% of flux
through citrate synthase (see Fig. 6). This small reverse flux in
perfused rat hearts contrasts with that measured in perfused rat livers
(~45%; see Ref. 7). This may be explained by the fact
that in the heart, NADP+-ICDH is almost exclusively located
in mitochondria, whereas in the liver, the cytosolic isoform represents
85% of total NADP+-ICDH activity (19) and
participates in fatty acid synthesis from glutamate (13).
Nevertheless, based on the following reasoning, we concluded low
reverse-flux values measured in perfused hearts reflected net flux
through reversal of NADP+-ICDH rather than simple isotopic
equilibration. The values of MPE M5 for tissue
-KG were more than
10-fold greater than those of citrate (Table 1). Rapid isotopic
equilibration between these two metabolites would result in similar
MPE values. Such a situation is observed for malate and fumarate where
rapid interconversion is catalyzed by fumarase (Table 1).
Unfortunately, we were unable to determine with precision the MPE M5
value of tissue isocitrate in all tissue samples because of its low
concentration. Furthermore, the small peak of isocitrate elutes from
the GC column very shortly after the much larger peak of citrate.
However, the analysis of some tissue samples revealed that the MPE of
citrate reflected that of isocitrate (data not shown), which supports a
reversible interconversion by aconitase.
In hearts perfused in the presence of octanoate with physiological
concentrations of glucose, insulin, lactate, pyruvate, and glutamate,
the magnitude of the reverse NADP+-ICDH flux, expressed
relative to the flux through citrate synthase, was increased by LFI as
predicted by Sazanov and Jackson (35) (see Fig. 6,
left). The reverse NADP+-ICDH flux was, however,
not affected by LFI when octanoate was replaced with the physiological
LCFA oleate complexed to fatty acid-poor albumin (see Fig. 6,
right). One possible explanation for the differential
effects of MCFA and LCFA on the reverse NADP+-ICDH flux
could be the inhibition of H+-transhydrogenases by
palmitoyl-CoA (12). In the proposed regulatory substrate
cycle between isocitrate and
-KG, H+-transhydrogenases,
whose activity occurs in the heart (36), generates NADPH
for NADP+-ICDH (see Fig. 1). Although palmitate was not
supplied exogenously to the heart, it could be present as endogenous
free fatty acids in our albumin preparation. Another possible
explanation is that the metabolism of MCFA and LCFA differently affects
the concentrations of effectors of enzymes involved in the metabolism
of citrate, isocitrate, and
-KG (18). In rat hearts
perfused under normoxia, state 4 respiration (high
NADH/NAD+ and ATP/Pi limited) prevails with
octanoate, whereas state 3 respiration (NADH limited) prevails with the
LCFA palmitate (17). A high rate of NADH production
(especially under conditions of limited O2 supply) could
shift the redox state of the NADP+ pool via
H+-transhydrogenases, and this in turn would lead to a
change in flux through the reversal of NADP+-ICDH.
Additional investigations are, however, needed to verify and
substantiate these explanations. The effects of MCFA could be of
clinical relevance because substitution of LCFA with MCFA in the diet
prevents the development of cardiac hypertrophy in spontaneously
hypertensive rats (11).
Our enzyme-activity data substantiate the notion of high
NADP+-ICDH activity in the heart (Fig. 7). The measured
activities varied in the following order: NADP+-ICDH > citrate synthase > aconitase > NAD+-ICDH. The
decreased activity of tissue aconitase by LFI (Fig. 7) is consistent
with inactivation of this enzyme by free radicals (25)
whose production is increased in LFI hearts (1). Because of the low activity of tissue NAD+-ICDH compared to that of
other enzymes, one may conclude that oxidation of isocitrate by
NADP+-ICDH would be needed to maintain normal CAC flux.
However, assuming that 1 g wet weight contains 0.2 g of
protein, maximal NAD+-ICDH activity is estimated to be 4 µmol/min × g wet weight. This activity is threefold greater
than CAC flux values, which are estimated [using the
M
O2 value (29)], to be
~1.5 and 0.1 µmol/min × g wet weight under normoxia and
LFI/NE, respectively.
The participation of NADP+-ICDH in mitochondrial isocitrate
oxidation in the heart is a controversial subject (6, 12, 33). Taken together, our 13C data demonstrate a net
substrate flux from
-KG to isocitrate through the reversal of
NADP+-ICDH as proposed by Sazanov and Jackson's hypothesis
(35). However, our data do not provide evidence for net
substrate flux through the following reactions: glutamate
-KG
isocitrate
citrate
mitochondrial citrate efflux, as
proposed by Thomassen et al. (42). Note that mitochondrial
citrate efflux occurs with a proton in exchange for malate and hence
would affect the electrochemical gradient. The presence of M5
isotopomers of citrate in heart tissue as well as in the effluent (not
shown) is more likely to be explained by isotopic equilibration between
citrate and isocitrate catalyzed by aconitase. The concentration ratio
of citrate to isocitrate measured in normoxic and LFI hearts perfused
with LCFA (70-90) or MCFA (30-33)
is greater than that found at equilibrium for the aconitase reaction in
vitro (15-20; see Ref. 19). This would be consistent
with isocitrate being pulled through the NAD+-ICDH
reaction. Using modeling data on [14C]bicarbonate
incorporation into citrate in perfused rat hearts, Nuutinen et al.
(26) concluded that citrate was being labeled through the
reversal of NADP+-ICDH, but the resulting net substrate
flux was in the forward reaction. The 13C protocol that
will quantitate the partitioning of isocitrate formed by the reversal
of NADP+-ICDH between oxidation by NAD+-ICDH
and citrate synthesis/efflux remains to be identified.
A reverse flux through NADP+-ICDH is inconsistent with an antioxidant role, where the enzyme would supply NADPH for regeneration of reduced glutathione by glutathione reductase. Such a role was proposed by Jo et al. (14) based on evidence obtained from NIH3T3 cells. However, the situation differs in the heart, where the mitochondrial NADPH/NADP+ ratio is high (>50; Refs. 19, 41) compared with <1 in NIH3T3 cells. Because NADPH potentiates the inhibition of NAD+-ICDH by NADH, reverse NADP+-ICDH activity could be crucial to prevent a rise in the NADPH/NADP+ ratio, especially under conditions where NADH accumulates (for example, under state 4 respiration). It remains to be clarified as to whether cardiac mitochondrial NADP+-ICDH could be forced to participate in NADPH generation at least under some conditions. For example, it could occur when the supply of NADH limits the activity of H+-transhydrogenases and hence NADPH generation (15). Such a situation may prevail if oxidative stress is increased in normoxic hearts, especially under state 3 respiration when NADH supply also limits the mitochondrial respiratory chain. However, future studies should investigate the possibility of a modulation of the NADP+-ICDH by oxidative stress.
In summary, this study shows that 13C substrates and mass isotopomer analysis provide a dynamic picture of substrate fluxes through NADP+-ICDH in the rat heart perfused under normoxia or LFI. Our 13C data show that this reaction operates in the reverse direction of the CAC. A reverse NADP+-ICDH flux coupled with the H+-transhydrogenase activities may be crucial to the fine regulation of CAC activity and hence of energy production for contraction of the normoxic and O2-deprived heart.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Dr. John Chatham for helpful comments. Thanks are also due to Ovid Da Silva of the Research Support Office, Centre Hospitalier Universitaire de l'Université de Montréal, for editing this text.
| |
FOOTNOTES |
|---|
Part of this work was presented at the following meetings: Experimental Biology (1997), Biomedical Engineering Society (1998), International Congress on Pathophysiology (1998), and World Congress of the International Society for Heart Research (2001).
This study was supported by the Canadian Institutes of Health Research Grant 10816 (to C. Des Rosiers).
Present address of B. Comte: Chaire de Pharmacie, local 1727, Centre de Recherche de l'Hôpital Ste-Justine, 3175 Côte Ste-Catherine, Montréal, QC, Canada, H3T 1C5.
Address for reprint requests and other correspondence: C. Des Rosiers, Laboratoire du Métabolisme Intermédiaire, Y-3616, Centre hospitalier de l'Université de Montréal-Hôpital Notre-Dame, 1560 rue Sherbrooke Est, Montréal, QC, Canada, H2L 4M1 (E-mail: christine.des.rosiers{at}umontreal.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
June 6, 2002;10.1152/ajpheart.00287.2002
Received 1 April 2002; accepted in final form 30 May 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Brunet, J,
Boily MJ,
Cordeau S,
and
Des Rosiers C.
Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow.
Free Radic Biol Med
19:
627-638,
1995[ISI][Medline].
2.
Bünger, R,
Mallet RT,
and
Hartman DA.
Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart. Near-complete prevention of reperfusion contractile failure.
Eur J Biochem
180:
221-233,
1989[ISI][Medline].
3.
Cheung, PY,
Danial H,
Jong J,
and
Schulz R.
Thiols protect the inhibition of myocardial aconitase by peroxynitrite.
Arch Biochem Biophys
350:
104-108,
1998[ISI][Medline].
4.
Comte, B,
Vincent G,
Bouchard B,
and
Des Rosiers C.
Probing the origin of acetyl-CoA and oxaloacetate entering the citric acid cycle from the 13C labeling of citrate released by perfused rat hearts.
J Biol Chem
272:
26117-26124,
1997
5.
Comte, B,
Vincent G,
Bouchard B,
Jette M,
Cordeau S,
and
Des Rosiers C.
A 13C mass isotopomer study of anaplerotic pyruvate carboxylation in perfused rat hearts.
J Biol Chem
272:
26125-26131,
1997
6.
Dalziel, K,
and
Londesborough JC.
The mechanisms of reductive carboxylation reactions. Carbon dioxide or bicarbonate as substrate of nicotinamide-adenine dinucleotide phosphate-linked isocitrate dehydrogenase and malic enzyme.
Biochem J
110:
223-230,
1968[ISI][Medline].
7.
Des Rosiers, C,
Fernandez CA,
David F,
and
Brunengraber H.
Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver. Evidence from isotopomer analysis of citric acid cycle intermediates.
J Biol Chem
269:
27179-27182,
1994
8.
Des Rosiers, C,
Montgomery JA,
Desrochers S,
Garneau M,
David F,
Mamer OA,
and
Brunengraber H.
Interference of 3-hydroxyisobutyrate with measurements of ketone body concentration and isotopic enrichment by gas chromatography-mass spectrometry.
Anal Biochem
173:
96-105,
1988[ISI][Medline].
9.
Flagg, TP,
and
Nichols CG.
Sarcolemmal KATP channels in the dark: molecular mechanisms brought to light, but physiologic consequences still in the dark.
J Cardiovasc Electrophysiol
12:
1195-1198,
2001[ISI][Medline].
10.
Gabriel, JL,
Zervos PR,
and
Plaut GW.
Activity of purified NAD-specific isocitrate dehydrogenase at modulator and substrate concentrations approximating conditions in mitochondria.
Metabolism
35:
661-667,
1986[ISI][Medline].
11.
Hajri, T,
Ibrahimi A,
Coburn CT,
Knapp FF, Jr,
Kurtz T,
Pravenec M,
and
Abumrad NA.
Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy.
J Biol Chem
276:
23661-23666,
2001
12.
Hansford, RG,
and
Johnson RN.
The steady state concentrations of coenzyme A-SH and coenzyme A thioester, citrate, and isocitrate during tricarboxylate cycle oxidations in rabbit heart mitochondria.
J Biol Chem
250:
8361-8375,
1975
13.
Holleran, AL,
Briscoe DA,
Fiskum G,
and
Kelleher JK.
Glutamine metabolism in AS-30D hepatoma cells. Evidence for its conversion into lipids via reductive carboxylation.
Mol Cell Biochem
152:
95-101,
1995[ISI][Medline].
14.
Jo, SH,
Son MK,
Koh HJ,
Lee SM,
Song IH,
Kim YO,
Lee YS,
Jeong KS,
Kim WB,
Park JW,
Song BJ,
and
Huh TL.
Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase.
J Biol Chem
276:
16168-16176,
2001
15.
Kehrer, JP,
and
Lund LG.
Cellular reducing equivalents and oxidative stress.
Free Radic Biol Med
17:
65-75,
1994[ISI][Medline].
16.
Laplante, A,
Vincent G,
Poirier M,
and
Des Rosiers C.
Effects and metabolism of fumarate in the perfused rat heart: a 13C mass isotopomer study.
Am J Physiol Endocrinol Metab
272:
E74-E82,
1997
17.
Lerch, R.
Oxidative substrate metabolism during postischemic reperfusion.
Basic Res Cardiol
88:
525-544,
1993[ISI][Medline].
18.
Liu, YQ,
Tornheim K,
and
Leahy JL.
Shared biochemical properties of glucotoxicity and lipotoxicity in islets decrease citrate synthase activity and increase phosphofructokinase activity.
Diabetes
47:
1889-1893,
1998[Abstract].
19.
Lowenstein, JM.
The tricarboxylic acid cycle.
In: Metabolic Pathways, , edited by Greenberg DM.. New York: Academic, 1967, p. 147-267.
20.
Luo, H,
Shan X,
and
Wu J.
Expression of human mitochondrial NADP-dependent isocitrate dehydrogenase during lymphocyte activation.
J Cell Biochem
60:
495-507,
1996[ISI][Medline].
21.
Mann, DL.
Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive.
Prog Cardiovasc Dis
41:
1-8,
1998[ISI][Medline].
22.
Morgunov, I,
and
Srere PA.
Interaction between citrate synthase and malate dehydrogenase. Substrate channeling of oxaloacetate.
J Biol Chem
273:
29540-29544,
1998
23.
Neely, JR,
and
Morgan HE.
Relationship between carbohydrate and lipid metabolism and the energy balance of the heart muscle.
Annu Rev Physiol
36:
413-459,
1974[ISI].
24.
Nielsen, TT,
Henningsen P,
Bagger JP,
Thomsen PE,
and
Eyjolfsson K.
Myocardial citrate metabolism in control subjects and patients with coronary artery disease.
Scand J Clin Lab Invest
40:
575-580,
1980[ISI][Medline].
25.
Nulton-Persson, AC,
and
Szweda LI.
Modulation of mitochondrial function by hydrogen peroxide.
J Biol Chem
276:
23357-23361,
2001
26.
Nuutinen, EM,
Peuhkurinen KJ,
Pietilainen EP,
Hiltunen JK,
and
Hassinen IE.
Elimination and replenishment of tricarboxylic acid-cycle intermediates in myocardium.
Biochem J
194:
867-875,
1981[ISI][Medline].
27.
Opie, LH.
Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia.
Circ Res
38:
I52-I74,
1976[Medline].
28.
Panchal, AR,
Comte B,
Huang H,
Dudar B,
Roth B,
Chandler M,
Des Rosiers C,
Brunengraber H,
and
Stanley WC.
Acute hibernation decreases myocardial pyruvate carboxylation and citrate release.
Am J Physiol Heart Circ Physiol
281:
H1613-H1620,
2001
29.
Panchal, AR,
Comte B,
Huang H,
Kerwin T,
Darvish A,
Des Rosiers C,
Brunengraber H,
and
Stanley WC.
Partitioning of pyruvate between oxidation and anaplerosis in swine hearts.
Am J Physiol Heart Circ Physiol
279:
H2390-H2398,
2000
30.
Peuhkurinen, KJ,
Takala TE,
Nuutinen EM,
and
Hassinen IE.
Tricarboxylic acid cycle metabolites during ischemia in isolated perfused rat heart.
Am J Physiol Heart Circ Physiol
244:
H281-H288,
1983
31.
Randle, PJ,
England PJ,
and
Denton RM.
Control of the tricarboxylate cycle and its interactions with glycolysis during acetate utilization in rat heart.
Biochem J
117:
677-695,
1970[ISI][Medline].
32.
Randle, PJ,
and
Tubbs PK.
Carbohydrate and fatty acid metabolism.
In: Handbook of Physiology. The Cardiovascular System. The Heart. Bethesda, MD: Am. Physiol. Soc, 1979, sect. 2, vol. I, chapt. 23, p. 805-844.
33.
Reynolds, CH,
Kuchel PW,
and
Dalziel K.
Equilibrium binding of coenzymes and substrates to nicotinamide-adenine dinucleotide phosphate-linked isocitrate dehydrogenase from bovine heart mitochondria.
Biochem J
171:
733-742,
1978[ISI][Medline].
34.
Rinaldi, CA,
and
Hall RJ.
Myocardial stunning and hibernation in clinical practice.
Int J Clin Pract
54:
659-664,
2000[ISI][Medline].
35.
Sazanov, LA,
and
Jackson JB.
Proton-translocating transhydrogenase and NAD- and NADP-linked isocitrate dehydrogenases operate in a substrate cycle which contributes to fine regulation of the tricarboxylic acid cycle activity in mitochondria.
FEBS Lett
344:
109-116,
1994[ISI][Medline].
36.
Sazanov, LA,
and
Jackson JB.
Cyclic reactions catalysed by detergent-dispersed and reconstituted transhydrogenase from beef-heart mitochondria; implications for the mechanism of proton translocation.
Biochim Biophys Acta
1231:
304-312,
1995[Medline].
37.
Schömig, A,
and
Richardt G.
The role of catecholamines in ischemia.
J Cardiovasc Pharmacol
16, Suppl5:
S105-S112,
1990.
38.
Schömig, A,
and
Richardt G.
Cardiac sympathetic activity in myocardial ischemia: release and effects of noradrenaline.
Basic Res Cardiol
85, Suppl1:
9-30,
1990[ISI][Medline].
39.
Schulz, H.
Regulation of fatty acid oxidation in heart.
J Nutr
124:
165-171,
1994
40.
Starnes, JW,
Wilson DF,
and
Erecinska M.
Substrate dependence of metabolic state and coronary flow in perfused rat heart.
Am J Physiol Heart Circ Physiol
249:
H799-H806,
1985
41.
Sundqvist, KE,
Heikkila J,
Hassinen IE,
and
Hiltunen JK.
Role of NADP+ (corrected)-linked malic enzymes as regulators of the pool size of tricarboxylic acid-cycle intermediates in the perfused rat heart.
Biochem J
243:
853-857,
1987[ISI][Medline].
42.
Thomassen, AR,
Nielsen TT,
Bagger JP,
and
Henningsen P.
Myocardial exchanges of glutamate, alanine and citrate in controls and patients with coronary artery disease.
Clin Sci (Lond)
64:
33-40,
1983[Medline].
43.
Vincent, G,
Comte B,
Poirier M,
and
Des Rosiers C.
Citrate release by perfused rat hearts: a window on mitochondrial cataplerosis.
Am J Physiol Endocrinol Metab
278:
E846-E856,
2000
44.
Wanders, RJ,
van Doorn HE,
and
Tager JM.
The energy-linked transhydrogenase in rat liver in relation to the reductive carboxylation of 2-oxoglutarate.
Eur J Biochem
116:
609-614,
1981[ISI][Medline].
This article has been cited by other articles:
![]() |
A. Beausejour, V. Houde, K. Bibeau, R. Gaudet, J. St-Louis, and M. Brochu Renal and cardiac oxidative/nitrosative stress in salt-loaded pregnant rat Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1657 - R1665. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Sharma, J. Sun, L. L. Howard, A. G. Williams Jr., and R. T. Mallet Oxidative stress reversibly inactivates myocardial enzymes during cardiac arrest Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H198 - H206. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. R. Dudley, M. Khairallah, S. Mohammed, L. Lands, C. Des Rosiers, and B. J. Petrof Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R704 - R710. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Okere, T. A. McElfresh, D. Z. Brunengraber, W. Martini, J. P. Sterk, H. Huang, M. P. Chandler, H. Brunengraber, and W. C. Stanley Differential effects of heptanoate and hexanoate on myocardial citric acid cycle intermediates following ischemia-reperfusion J Appl Physiol, January 1, 2006; 100(1): 76 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Battista, E. Calvo, A. Chorvatova, B. Comte, J. Corbeil, and M. Brochu Intra-uterine growth restriction and the programming of left ventricular remodelling in female rats J. Physiol., May 15, 2005; 565(1): 197 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Labarthe, M. Khairallah, B. Bouchard, W. C. Stanley, and C. Des Rosiers Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1425 - H1436. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. MacDonald, L. A. Fahien, L. J. Brown, N. M. Hasan, J. D. Buss, and M. A. Kendrick Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E1 - E15. [Abstract] [Full Text] [PDF] |